Literature DB >> 11236232

The impact of state policy on the costs of HIV infection.

D P Goldman1, J Bhattacharya, A A Leibowitz, G F Joyce, M F Shapiro, S A Bozzette.   

Abstract

There is substantial variation in the generosity of public assistance programs that affect HIV+ patients, and these differences should affect the economic outcomes associated with HIV infection. This article uses data from a nationally representative sample of HIV+ patients to assess how differences across states in Medicaid and AIDS Drug Assistance Programs (ADAP) affect costs and labor market outcomes for HIV+ patients in care in that state. Making ADAP programs more generous in terms of drug coverage would reduce per patient total monthly costs, mainly through a reduction in hospitalization costs. In contrast, expanding ADAP eligibility by increasing the income threshold would increase the total cost of care. Expanding eligibility for Medicaid through the medically needy program would increase per patient total costs, but full-time employment would increase and so would monthly earnings. The authors conclude that more generous state policies toward HIV+ patients--especially those designed to provide access to efficacious treatment--could improve the economic outcomes associated with HIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236232     DOI: 10.1177/107755870105800102

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  6 in total

1.  [Economic aspects of ambulatory and inpatient treatment of HIV positive patients].

Authors:  M Stoll; R E Schmidt
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

2.  Effective HIV treatment and the employment of HIV(+) adults.

Authors:  Dana P Goldman; Yuhua Bao
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

3.  Are community-based pharmacists underused in the care of persons living with HIV? A need for structural and policy changes.

Authors:  Jennifer Kibicho; Steven D Pinkerton; Jill Owczarzak; Lucy Mkandawire-Valhmu; Peninnah M Kako
Journal:  J Am Pharm Assoc (2003)       Date:  2015 Jan-Feb

4.  Economic benefits of the United States' AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities.

Authors:  Kathleen A McManus; Andrew Strumpf; Amy Killelea; Tim Horn; Auntré Hamp; Jessica Keim-Malpass
Journal:  Prev Med Rep       Date:  2022-08-29

5.  State policy influence on the early diffusion of buprenorphine in community treatment programs.

Authors:  Lori J Ducharme; Amanda J Abraham
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-20

6.  Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment.

Authors:  Bruce R Schackman; Kenneth A Freedberg; Sue J Goldie; Milton C Weinstein; Katherine Swartz
Journal:  Health Care Financ Rev       Date:  2005
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.